PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Dihydroxytryptamines”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,243 records · Page 69Linked to original sources

Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site.

The hypothesis that serotonin (5-HT)-stimulated phosphoinositide hydrolysis is mediated by the 5-HT-2 binding site in cerebral cortex was tested by comparing antagonist Kd values determined by Schild analyses with Ki values at the 5-HT-2 binding site. A significant correlation was found between Kd values and Ki values at competing for 3H-ketanserin binding (R = 0.98), suggesting that the phosphoinositide-linked receptor and the 5-HT-2 site are identical. The 5-HT-2-mediated phosphoinositide response was then used as a measure of 5-HT-2 receptor sensitivity after in vivo treatments that alter the availability of 5-HT. Chronic treatment with the 5-HT-2 antagonist mianserin resulted in a significant decrease (52%) in the density of 5-HT-2 binding sites and a significant decrease (49%) in the maximal phosphoinositide hydrolysis response to 5-HT. Depletion of 5-HT levels with para-chlorophenylalanine or chemical denervation of serotonergic neurons with 5,7-dihydroxytryptamine had no significant effect upon 5-HT-2 receptor density or upon the phosphoinositide response to 5-HT. These data suggest that changes or lack of changes in 5-HT-2 receptor density following in vivo manipulations reflect the functional state of the receptor.

5,7-Dihydroxytryptamine↗

Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat.

Transcortical dialysis in awake unrestrained rats has been used to evaluate the functional role of differently located alpha-2 adrenoceptors in mediating the action of the alpha-2 adrenoceptor antagonist idazoxan on cerebral noradrenaline release. Basal efflux of noradrenaline collected by a cortically implanted dialysis fiber was stable over a period of 4 days. Systemic injections of idazoxan (20 mg/kg i.p.) increased cortical noradrenaline efflux. This effect was potentiated by pretreatment with the noradrenaline uptake blocker desipramine (20 mg/kg i.p.). Local cortical infusion of (10(-4) M idazoxan which provides a theoretical extracellular administration of 4 to 48 microM) via the dialysis fiber, thus eliminating the potential contribution of somatodendritic alpha-2 adrenoceptors, also elevated cortical noradrenaline efflux. Desipramine (20 mg/kg i.p.) potentiated this effect. Four days after lesioning cortical cell bodies with ibotenic acid (20 min infusion of 10(-4) M ibotenic acid via the dialysis fiber), both systemic injections and local cortical infusions of idazoxan were still effective in increasing cortical noradrenaline efflux. Lesion of serotonergic afferents to the cerebral cortex (by i.c.v. injection of 5,7-dihydroxytryptamine) or of cortical cholinergic afferents (by bilateral electrocoagulation of the nucleus basalis magnocellularis) did not affect the ability of cortical idazoxan infusion to stimulate noradrenaline efflux. The results suggest that the effects of idazoxan on cortical noradrenaline release are mediated primarily by alpha-2 adrenoceptors on noradrenergic nerve terminals, rather than by those located postsynaptically, somatodendritically or on the terminals of other neuronal inputs to the cerebral cortex.

5,7-Dihydroxytryptamine↗

Modification of electroshock convulsive responses and thresholds in neonatal rats after brain monoamine reduction.

Modification of electroshock (60 Hz; a.c.) convulsive responses and thresholds by monoamine-reducing drugs was investigated in developing rats. Throughout postnatal development, tetrabenazine (TBZ) reduced brain monoamines and increased the severity of motor responses to electroshock. The predominant maximal response in control pups progressed from hyperkinesia (day 1) to clonic convulsions (day 3) and tonic forelimb (day 7) and hindlimb (day 19) extension. The pattern in TBZ-treated pups progressed from tonic forelimb extension (day 1) to tonic hindlimb extension (day 7). On day 7, TBZ reduced the thresholds for clonic (CT) and tonic convulsions (TT) to 41 and 24% of control, respectively. Reserpine (1.25 mg/kg, 24 hours) decreased the TT but not the CT; TBZ, 4 hours before reserpine, prevented this decrease. A higher dose of reserpine (2.5 mg/kg) decreased both the CT and TT. On day 8, TBZ (25 mg/kg, 4 hours) decreased the TT (46% control); L-dihydroxyphenylalanine, but not 5-hydroxytryptophan prevented this decrease. Intracisternal 6-hydroxydopamine reduced the TT on day 8, while intracisternal 5,7-dihydroxytryptamine had no effect despite a 46% reduction in serotonin. The results indicate that in the neonatal rat brain, monoaminergic systems are sufficiently mature to attenuate electroshock convulsive responses, perhaps by limiting propagation of seizure discharge.

5,7-Dihydroxytryptamine↗

Evidence that serotonin mediates some behavioral effects of amphetamine.

In the rat, d-amphetamine sulfate (15--80 mg/kg) causes numerous behavioral effects including simultaneous side-to-side head weaving or head tremor, forepaw padding and splayed hindlimbs. These signs are strikingly similar to a behavioral syndrome caused by intense serotonin (5-HT) receptor activation. Experiments were designed to determine whether some of the numerous effects of amphetamine on behavior can be ascribed to actions of the drug on 5-HT mechanisms. Catecholamine depletion with alpha-methyl-p-tyrosine did not prevent the amphetamine syndrome. However, 5-HT depletion with 5,7-dihydroxytryptamine or with p-chlorophenylalanine did prevent the syndrome. The degree of syndrome inhibition by p-chlorophenylalanine was correlated with the extent of 5-HT depletion. Normal responsiveness to amphetamine in p-chlorophenylalanine-treated rats was restored by 5-hydroxytryptophan, the precursor of 5-HT. Furthermore, methysergide, a 5-HT receptor blocker, prevented the amphetamine syndrome, whereas catecholamine blockers, phenoxybenzamine and pimozide, were ineffective. The results suggest that when amphetamine causes the signs of the syndrome it does so by activating 5-HT receptors in the brain, probably by displacement of endogenous 5-HT.

5,7-Dihydroxytryptamine↗

Influence of serotonin on the immune response.

The present study investigates the influence of pharmacological agents known to regulate biosynthesis of the neurotransmitter, serotonin (5-hydroxytryptamine, 5-HT) on the primary antibody response to sheep red blood cells (SRBC) in the CBA mouse. Systemic administration of 5-HT (4-100 mg/kg) or its precursor, 5-hydroxytryptophan (5-HTP, 50-400 mg/kg), 30-60 min before immunization resulted in dose-dependent suppression of both the IgM and IgG plaque-forming cell (PFC) response to SRBC. Conversely, para-chlorophenylalanine (PCPA, 250 mg/kg), which inhibits the rate-limiting enzyme (tryptophan hydroxylase) in 5-HT biosynthesis, markedly enhanced IgM and IgG antibody production when injected 48 hr prior to antigen. Effects of these drugs on immune processes appeared independent of observed changes in plasma corticosterone levels. Further, immune function was preserved following selective depletion of brain serotonin through intracisternal injection of the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) in mice pretreated with desmethylimipramine (DMI). Thus, immunomodulation by serotonin appears to be mediated via peripheral mechanism(s).

5,7-Dihydroxytryptamine↗

[Effect of 5,6-hydroxytryptamine and various light schedules on the hypothalamo-hypophyseo-gonadal system of the female rat].

Hypothalamic luliberin and plasma lutropin concentration were studied under normal light-darkness cycle or under constant illumination in rats. Some of them were injected with 5,6-dihydroxytryptamine (5,6-HTA) into the lateral brain ventricle. Constant illumination led to a persistent oestrus with a significant drop in plasma lutropin and a decrease in hypothalamic luliberin. Destruction of serotoninergic terminals with 5,6-HTA resulted in an opposite effect and prevented to some extent inhibiting influence of constant illumination. Luliberin synthesis and secretion seem to be suppressed by serotoninergic nerve terminals on the luliberin producing cells as well as by serotonin reaching the hypothalamus from the pineal gland.

5,6-Dihydroxytryptamine↗

Application of [125I]iodocyanopindolol to measure 5-hydroxytryptamine1B receptors in the brain of the rat.

In this study, [125I]iodocyanopindolol ([125I]ICYP), in the presence of isoproterenol, was used to label 5-hydroxytryptamine1B (5-HT1B) receptors in homogenates of the cortex, substantia nigra and caudate-putamen of the rat. The determination of the appropriate concentrations of isoproterenol required to block optimally beta adrenoceptors whereas producing minimal occupancy of 5-HT1B receptors was achieved by generating isotherms for isoproterenol at multiple concentrations of [125I]ICYP. When different concentrations of isoproterenol were used with increasing concentrations of [125I]ICYP, a linear Scatchard transformation of the saturation curve was achieved, even with ligand concentrations about 6-fold greater than the KD for [125I]ICYP. Competition for [125I]ICYP (100 pM) labeled binding sites by 15 serotonin agonists or antagonists was adequately described by a single site model, and the affinity of these drugs for the site labeled by [125I]ICYP was similar to that determined previously when using indirect methods to label 5-HT1B receptors. Serotonin itself showed high affinity for this binding site as did two antagonists, metergoline and methiothepin. By contrast, drugs thought to be selective for the 5-HT1A receptor (e.g., 8-hydroxy-2-(di-n-propylamino)tetralin, buspirone and spiperone) showed very weak affinity for the binding site labeled with [125I]ICYP. The effect of nucleotide regulation on [125I]ICYP binding at 5-HT1B receptors also was evaluated. It was determined that GTP had little effect on the binding of [125I]ICYP, reducing total binding by only 15% and shifting the displacement curve of 5-HT by a factor of less than two. The regulation of 5-HT1B receptors, labeled by [125I]ICYP, also was evaluated. Intraventricular injections of 5.7-dihydroxytryptamine increased significantly the number of 5-HT1B receptors in the caudate-putamen; this treatment had no effect on 5-HT1B binding sites either in the cortex or substantia nigra. The regulatable binding site for [125I]ICYP in the caudate-putamen had a pharmacological profile very similar to that of the 5-HT1B binding site in the cortex. [125I]ICYP appears to be a useful ligand to measure 5-HT1B receptors in the brain of the rat. The localized increase in 5-HT1B receptors in the caudate-putamen after destruction of central serotonergic neurons might indicate that the majority of 5-HT1B receptors in this area of brain are not located on serotonergic nerve terminals.

5,7-Dihydroxytryptamine↗

Morphological and immunocytochemical identification of indoleamine-accumulating neurons in the cat retina.

The type and distribution of indoleamine-accumulating neurons were studied in the cat retina. The neurons were characterized by their capacity to take up an exogenous indoleamine, 5,6-dihydroxytryptamine, which could then be visualized using formaldehyde-induced fluorescence. Under direct microscopic control, intracellular injection of Lucifer yellow into the labeled cells revealed that the indoleamine-accumulating neurons comprise 2 distinct morphological types of amacrine cell and 1 class of ganglion cell. The dendritic morphology and retinal distribution of these cells were studied in detail. The proportion of retinal cells that accumulate 5-HT was measured using 5-HT (5-hydroxytryptamine) preloading in vitro and immunocytochemistry with an anti-5-HT antibody. Only 1 type of amacrine cell showed uptake of 5-HT at a concentration of 10(-7) M. Cells containing endogenous 5-HT were not detected by immunocytochemistry.

5,6-Dihydroxytryptamine↗

Labeling in vivo of serotonin uptake sites in rat brain after administration of [3H]cyanoimipramine.

The properties of sites in rat brain labeled in vivo after administration of [3H]cyanoimipramine ([3H]CN-IMI) have been studied. The radioactivity in hypothalamus and cortex 20 min to 2 hr after [3H]CN-IMI administration was reduced in rats pretreated with chlorimipramine (10 mg/kg) 5 min before [3H]CN-IMI. No effect of chlorimipramine pretreatment was seen in the cerebellum; levels of radioactivity in this tissue were subtracted from total levels in hypothalamus and cortex to define specific binding. This represented approximately 50 and 30% of total binding in hypothalamus and cortex, respectively. Specific binding in hypothalamus and cortex was reduced by a number of drugs which are potent blockers of serotonin uptake and the binding was inhibited in a stereoselective manner by the stereoisomers of norzimelidine. In contrast, pretreatment with drugs which are weak inhibitors of serotonin uptake had no effect on specific binding. Experiments using increasing doses of [3H]CN-IMI showed that the binding in vivo was saturable. Lesioning rats with the serotonin neurotoxin 5,7-dihydroxytryptamine resulted in an 80% decrease in the specific binding in hypothalamus and a 35% decrease in cortex. The potencies of drugs to inhibit the specific binding of [3H]CN-IMI in vivo were highly correlated with their previously published potencies for inhibiting serotonin uptake in human blood platelets in vitro and for preventing the serotonin depletion induced by 4-methyl-alpha-ethyl-metatyramine in vivo. These results indicate that [3H]CN-IMI can be given to rats to provide a measure of serotonin uptake sites in the central nervous system in vivo.

5,7-Dihydroxytryptamine↗

[Role of the giant serotonin-containing cell of the cerebral ganglion in the edible snail in organizing its food-acquiring behavior].

By adding dopamine or serotonin to a bath with snail's isolated nervous system and by intracellular activation of giant cerebral serotonergic cells it was established in neurophysiological experiments that, in spite of activating effect of serotonin on buccal motorneurones, dopamine is the transmitter triggering feeding movements of the buccal mass and feeding pattern in buccal motorneurones. This conclusion is confirmed by behavioural experiments in which an experimental group was injected by neruotoxin 5,6-dihydroxytryptamine selectively impairing serotonergic neurones. The consumatory phase of feeding (triggered by dopamine) did not change in treated animals, while the appetitive phase was significantly impaired. It was noted that the giant metacerebral cell was activated during burst activity in buccal motoneurones. The conclusion is made that giant serotonergic cerebral cells only modulate but do not trigger the feeding behaviour in the snail Helix lucorum.

5,6-Dihydroxytryptamine↗

Electrophysiological identification of serotonergic neurons in the rat nucleus raphe magnus.

In the present study, antidromically activated raphe-spinal neurons in the nucleus raphe magnus are found to exhibit a wide range of conduction velocities and spontaneous discharge rates. The unit activities observed in control rats have been compared with those in 5,6-dihydroxytryptamine (a specific neurotoxin to serotonergic cells)-pretreated animals. It is found that the units conducting at slower than 12 m/sec and discharging at rates of less than 3 Hz often found in control rats are not found in drug-pretreated animals, and are thus presumed to be serotonergic. In addition, the regularity of spontaneous discharges of units has been evaluated by testing the coefficient of variability of spike intervals. These results indicate that the slow-conducting units discharge less regularly than the fast-conducting ones.

5,6-Dihydroxytryptamine↗

A system of indoleamine-accumulating neurons in the rabbit retina.

The indoleamine-accumulating neurons of the rabbit retina were labeled by intraocular injection of 5,7-dihydroxytryptamine (5,7-DHT). The retinas were fixed with 2.5% paraformaldehyde and 0.2% glutaraldehyde and inspected by fluorescence microscopy. Five kinds of cell accumulated the indoleamine. They were labeled to essentially the same brightness and remained so despite variations in the concentration at which 5,7-DHT had been applied or the duration of its application. Experiments in which 5,7-DHT was applied to retinas incubated in vitro gave identical results. To see the whole shape of the cells, we visually guided micropipettes to the fluorescent cell bodies and injected the cells with Lucifer yellow CH. To study the cells as a population, we used a new method in which the fluorescence of 5,7-DHT is photochemically converted to an insoluble diaminobenzidine product. The dendrites of all of the indoleamine-accumulating cells were then simultaneously visible. Used together, these techniques revealed an interrelated system of indoleamine-accumulating neurons. All of the cells contribute processes to a dendritic plexus that lies at the inner margin of the inner plexiform layer. The plexus is roughly 4 micron thick. It is pierced by the stalks of the Müller cells and is occasionally interrupted by ganglion cell bodies, where they extend above the average margin of the ganglion cell layer. Otherwise it fills much of the space at the junction of the plexiform and ganglion cell layers. The type 1 and type 2 cells are amacrine cells with cell bodies at the inner margin of the inner nuclear layer. They have 5-8 radially branching primary dendrites which extend horizontally across the inner plexiform layer before descending to join the dendritic plexus. They differ from each other in cell body shape, dendritic morphology, and the course of their dendrites within the inner plexiform layer. Each has a "displaced" counterpart, with a morphology similar to the type 1 or type 2 cell but with a cell body located in the ganglion cell layer. The displaced cells are separate functional elements because, in contrast to the type 1 and type 2 cells, they have no dendrites (and hence can have no synaptic connections) in the outer part of the inner plexiform layer. The fifth kind of cell (type 3) appears not to have been described before. Its cell body is located at the outer margin of the inner nuclear layer.(ABSTRACT TRUNCATED AT 400 WORDS)

5,7-Dihydroxytryptamine↗

Antinociceptive and behavioral effects of leu-enkephalin (LENK) or D-Ala2-met-enkephalinamide (DAMEA) in rats after central chemical sympathectomy or serotoninectomy.

In rats with central chemical sympathectomy induced by two injections into the lateral brain ventricle (icv) of 250 micrograms of 6-hydroxydopamine or with central chemical serotoninectomy induced by 75 micrograms of 5,6-dihydroxytryptamine icv the antinociceptive and behavioral effects of LENK (200 micrograms icv) or DAMEA (10 or 20 micrograms icv) were examined. The chemical lesion of central noradrenaline or dopamine neurons or specific lesion of serotonin neurons abolished antinociceptive effects of LENK and DAMEA. Both peptides inhibited exploratory activity of rats. Central chemical serotoninectomy but not sympathectomy reversed some behavioral effects induced by LENK and DAMEA. These results suggest modulatory influence of the central noradrenaline and serotonin neurons in the antinociceptive mechanism of action of enkephalins and the participation of the central serotonin neurons on the behavior of rats induced by enkephalins.

5,6-Dihydroxytryptamine↗

Antinociceptive effect of intracerebroventricularly administered histamine in rats.

Intracerebroventricularly (icv) administered histamine produced a dose-related antinociceptive effect in rats, using the rat tail-hot wire technique as the experimental parameter. The H1-receptor agonist, 2-methyl-histamine, given icv, also induced marked antinociception, whereas the H2-receptor agonist, 4-methylhistamine, produced relatively weaker and transient antinociception. Histamine-induced antinociception was significantly inhibited by mepyramine, a H1-receptor antagonist, but not by cimetidine, a H2-receptor antagonist. 5,6-Dihydroxytryptamine, a specific serotonin neuronolytic agent, and p-chlorophenylalanine, which selectively inhibits serotonin synthesis, markedly inhibited the antinociceptive effect of histamine, which was also attenuated by naloxone, an antagonist for endogenous opioid receptors, and by dexamethasone, which is known to reduce central endorphin concentrations. On the contrary, the effect of histamine was potentiated by adrenalectomy and by metyrapone, an inhibitor of endogenous corticoid synthesis, which are known to enhance central endorphins.

5,6-Dihydroxytryptamine↗

[Effect of the destruction of the brain serotoninergic system on the alcohol consumption by rats in the early periods of experimental alcoholism].

Albino noninbred rats were divided into groups, according to the duration of alcoholic anesthesia (4.5 g/kg i.p.), of predisposed (195.6 min) and non-predisposed (69.1 min) to voluntary intake of alcohol. Another group included animals screened for 21 days according to the level of intake of 15% ethanol under the conditions of free choice between alcohol and water (6.15 and 2.62 g/kg pure ethanol per day, respectively). The animals were subjected to electro-coagulation of the dorsal or magnus raphe nucleus or were injected with 5,6-dihydroxytryptamine--DNT (75 micrograms/microliters) into the ventricles of the brain. It was established that in rats non-predisposed to alcohol intake, the destruction of the raphe nuclei, of the dorsal in particular, or injection of DOT to animals with a weak alcoholic motivation produces a dramatic increase in alcohol intake. In alcohol intake predisposed rats and in animals with a high level of alcohol use, analogous exposures do not bring about any significant differences in alcohol intake. The data obtained indicate that the reduced serotonin content in the brain is associated with an increase in the level of alcoholic motivation.

5,6-Dihydroxytryptamine↗

Functional recuperation of the serotoninergic innervation in the rat locus coeruleus.

1. 5,6-dihydroxytryptamine (5,6-DHT) or a lesion of the raphe centralis superior (RCS) cause significant decreases in the serotonin (5-HT) content and significant increases in the tyrosine hydroxylase activity in the locus coeruleus (LC) of the rat. This suggests that noradrenaline (NA) synthesis is controlled by serotonin-containing neurons in the raphe system via their terminals in the LC. 2. Radioautography after intraventricular infusion of tritiated serotonin (3H-5-HT) and biochemical determinations of endogenous 5-HT content showed an almost complete disappearance of serotoninergic axonal varicosities and content in the LC region 10-15 days after intraventricular administration of 75 micrograms of 5,6-DHT. Two to 4 months after neurotoxin administration, 5-HT fibers had regrown in the LC but, contrary to the normal innervation pattern, the majority of them invaded the medial most portion of the nucleus and the adjacent subependymal region. The LC region regained almost all of its endogenous 5-HT content in the same time period. 3. Functional recuperation of these 5-HT fibers was demonstrated by the fact that the RCS had, after regeneration, the same functional control on NA synthesis as in the normal animal.

5,6-Dihydroxytryptamine↗

In vivo measurements by differential pulse voltammetry of extra-cellular 5-hydroxyindoleacetic acid in the rat brain.

The use of differential pulse voltammetry, performed with electrochemically treated carbon fiber electrodes, enables us to detect in vitro or in vivo, in the striatum of anaesthetized rats, an oxidation peak (3) at a potential of + 300 mV. Electrolytic or 5-7-dihydroxytryptamine lesions of the medial forebrain bundle are followed by a decrease of 59 and 62% respectively of this peak. Biochemical measurements are significantly correlated with the measured peak (3) and decreases. Thus, peak (3) increases obtained after injection of L-tryptophan and/or Reserpine, as well as the decreases observed after injection of Clorgyline or 3-hydroxybenzylhydrazine, confirm that peak (3) is dependent upon 5-hydroxyindoleacetic acid concentration. The detection of a peak (3) in the cerebrospinal fluid and its increase after injection of Probenecid reinforce this conclusion.

5,7-Dihydroxytryptamine↗

[Interactions of cerebral serotonin and catecholamines].

It has been demonstrated that the administration of large doses of dopa or 5-hydroxytryptophan (5-HTP) affected not only dopamine (DA) or serotonin (5-HT) neurons but also other neurons. This report concerns the effects of tryptophan, 5-HTP or dopa on concentrations of 5-HT, DA, norepinephrine, and their metabolites in p-chlorophenylalanine-, 5,7-dihydroxytryptamine (5,7-DHT)- or non-treated rat brain. The results were as follows: 1) When the brain DA levels increased more than six-fold after the i.p. administration of l-dopa, the brain 5-HT levels significantly decreased, and 5-hydroxyindoleacetic acid (5-HIAA) levels significantly increased. 2) In the nerve ending fraction of rat brain, the administration of l-dopa induced the largest increase of DA levels in the striatum, while administration of dl-5-HTP produced the largest increase of 5-HT levels in the hypothalamus. These results suggest that the distribution of newly synthesized 5-HT or DA after the administration of 5-HTP or dopa, respectively, depends not only on that of aromatic l-amino acid decarboxylase, but also on that of nerve cells which selectively take up 5-HTP or dopa or that of synaptic vesicles which selectively take up 5-HT or DA. 3) The large doses of 5-HTP administration to 5,7-DHT pretreated rats induced the largest increase of 5-HT levels in the striatum. Thus, results in the present study indicate that the distribution of DA or 5-HT after the administration of dopa or 5-HTP, respectively, depends on the doses of dopa or 5-HTP given as well as the presence or absence of the lesioned 5-HT or DA neurons.

5,7-Dihydroxytryptamine↗